Marinus Pharma

Today, we shared topline results from our Phase 3 TrustTSC trial. Read more in our press release: https://lnkd.in/eqQAegfy We sincerely appreciate the patients, investigators, clinical sites and collaborators who supported and participated in this trial.

At just under a year old, Judith was diagnosed with CDKL5 deficiency disorder, a rare, X-linked DEE characterized by early-onset, refractory seizures and severe global developmental impairment. A special thank you to Medical Stories for bringing Judith’s story to light and promoting awareness of this rare disease. Watch the full episode, which is also airing via the PBS local stations, to learn more. https://lnkd.in/epJT7FkT

We recently hosted our virtual “PetOberfest” event where employees shared adorable photos of their pets and even brought some furry friends on camera to raise money for Canine Partners for Life! We’re proud to support this incredible organization and its mission to create life-changing partnerships with service and companion dogs, bringing independence and greater quality of life to those they work with, including individuals with epilepsy. Here are some photos!

Today, we presented data from our pivotal Phase 3 RAISE trial in refractory status epilepticus at the Neurocritical Care Society Annual Meeting. Learn more in our press release: https://lnkd.in/ebHVx8KA

Today, we announced that the USPTO issued Marinus a new method of treatment patent for ZTALMY titration regimens, further strengthening our IP estate. Learn more: https://lnkd.in/gBpaH4mw

Join us at the 2024 Neurocritical Care Society Annual Meeting where we will be presenting additional data from the pivotal Phase 3 RAISE trial and data from a retrospective claims-based analysis. Read more in our press release: https://lnkd.in/eqYYcqsM

Last week, we hosted our annual Investor and Analyst Day where we highlighted our clinical progress and commercial launch preparedness in tuberous sclerosis complex (TSC). Key takeaways include: - Updates from the fully enrolled Phase 3 TrustTSC trial, with topline data expected in the first half of Q4 2024. - New follow up data in patients who completed our Phase 2 TSC trial and entered the long-term extension. - Insights from market research and real-world data that underscore the unmet need in the TSC community.   Thank you to all who participated and contributed to the discussions. We remain focused on advancing research and improving outcomes for patients with rare genetic epilepsies and other neurodevelopmental disorders.   Access the webcast recording to learn more:

Today, during our 2024 Investor & Analyst Day, we’re discussing the significant progress we’re making in our mission to improve the lives of patients and families affected by rare genetic epilepsy disorders. Learn more in today’s press release: https://lnkd.in/ekgcp7hr

Our Investor & Analyst Day starts at 9:00 am ET tomorrow! We’re looking forward to sharing updates about our clinical progress and vision for the future. Members of the investment community can register for the event and view our webcast here: https://lnkd.in/e3UabeXx

Tomorrow, our Chairman and CEO, Scott Braunstein, and our CFO and COO, Steven Pfanstiel, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference. Register here for the webcast: https://lnkd.in/eGnsveCj